<DOC>
	<DOC>NCT00730379</DOC>
	<brief_summary>This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.</brief_summary>
	<brief_title>A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)</brief_title>
	<detailed_description>Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>You must have confirmed metastatic or advanced cancer that has not responded to standard therapy or where standard therapy does not exist In Part C, patients must have a diagnosis of advanced or metastatic colorectal adenocarcinoma or nonsmall cell lung cancer, and must have received at least 1 but no more than three prior systemic therapy treatment regimens You must be over the age of 18 years old You must have a ECOG status performance of 0 or 1 You must have good organ function You must be willing to have skin and/or tumor biopsies You have had cancer treatment within 4 weeks prior to entering the study or you still have bad side effects from previous therapies You have an active infection that requires treatment You are HIV positive or have a history of Hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>